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A B S T R A C T
Antimalarial resistance is an inevitable feature of control e!orts and a key threat to achieving malaria elim-
ination. Plasmodium falciparum, the deadliest of several species causing human malaria, has developed re-
sistance to essentially all antimalarials. This study sought to investigate the prevalence of molecular markers
associated with resistance to sulfadoxine-pyrimethamine (SP) and artemether-lumefantrine (AL) in Southern and
Western provinces in Zambia. SP is used primarily for intermittent preventive treatment during pregnancy, while
AL is the first-line antimalarial for uncomplicated malaria in Zambia. Blood samples were collected from
household members of all ages in a cross-sectional survey conducted during peak malaria transmission, April to
May of 2017, and amplified by polymerase chain reaction (PCR). Amplicons were then analysed by high-re-
solution melt following PCR to identify mutations associated with SP resistance in the P. falciparum dihy-
drofolate reductase (Pfdhfr) and P. falciparum dihydropteroate synthase (Pfdhps) genes and lumefantrine re-
sistance in the P. falciparum multi-drug resistance 1 (Pfmdr1) gene. Finally, artemether resistance was assessed
in the P. falciparum Kelch 13 (PfK13) gene using nested PCR followed by amplicon sequencing. The results
showed a high frequency of genotypic-resistant Pfdhps A437G (93.2%) and Pfdhfr C59R (86.7%), N51I (80.9%),
and S108N (80.8%) of which a high proportion (82.4%) were quadruple mutants (Pfdhfr N51I, C59R, S108N
+Pfdhps A437G). Pfmrd1 N86Y, Y186F, and D1246Y - NFD mutant haplotypes were observed in 41.9% of
isolates. The high prevalence of quadruple dhps/dhfr mutants indicates strong antifolate drug pressure from SP
or other drugs (e.g., co-trimoxazole). Three samples contained PfK13 mutations, two synonymous (T478 and
V666) and one non-synonymous (A578S), none of which have been associated with delayed clearance. This
suggests that artemisinin remains e"cacious in Zambia, however, the moderately high prevalence of approxi-
mately 40% Pfmdr1 NFD mutations calls for close monitoring of AL.
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Antimalarial drug resistance is a key threat to eliminating malaria.
Strategies to eliminate the disease include early case diagnosis and
prompt treatment using an e!ective and e"cacious antimalarial
(MOH, 2017). For Zambia, mass drug administration (MDA) with an
artemisinin-based combination therapy (i.e., dihydroartemisinin-pi-
peraquine [DHAP]), given to populations of all ages with the exception
of children under three months of age, has been added as an accelerator
in Southern Province, an area selected for sub-national elimination
(MOH, 2017). Intermittent preventive treatment during pregnancy
(IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by the
World Health Organization in areas of Africa with moderate to high
malaria transmission. While artemisinin-based therapies (ACTs) are
used for treatment of malaria cases, namely artemether-lumefantrine
(AL) for uncomplicated malaria with DHAP as an alternative, and in-
jectable artesunate for severe malaria (MOH, 2014; WHO, 2015).
Resistance to SP has been reported in many countries, including
Uganda (Mbonye et al., 2015), Tanzania (Baraka et al., 2015), Kenya
(Hemming-Schroeder et al., 2018), Cameroon (Chauvin et al., 2015),
and Zambia (Siame et al., 2015). Resistance to SP is mediated by mu-
tations in two enzymes, namely Plasmodium falciparum dihydrofolate
reductase (Pfdhfr), which confers resistance to pyrimethamine, and P.
falciparum dihydropteroate synthetase (Pfdhps), which confers re-
sistance to sulfadoxine (Cowman et al., 1988; Marks et al., 2005;
Peterson et al., 1988). To reduce the likelihood of selection for re-
sistance, it is recommended to use drug combinations (Majori, 2004)
and regularly monitor drug e"cacy.
Zambia was the first African country to use AL as a first-line treat-
ment (Sipilanyambe et al., 2008). Between 1995 and 2005, chloroquine
(CQ) and SP were the first- and second-line treatments, respectively, for
uncomplicated malaria in Zambia (Bijl et al., 2000). In 2000, CQ re-
sistance was wide spread, with some areas of the country reporting
resistance in 58% of samples (Bijl et al., 2000).
Artemisinin resistance was first identified as a delayed clearance
phenotype in South East Asia (Ashley et al., 2014; Noedl et al., 2008).
The genetic basis for resistance was identified in the propeller domain
of the P. falciparum Kelch13 (Pfk13) gene, which is located on chro-
mosome 13, and encodes a 727 amino acid protein (Ariey et al., 2014).
Currently, nine Pfk13 mutations have been validated as artemisinin-
resistant markers, with an additional 11 associated with the resistant
phenotype; 18 additional mutations have been isolated but not eval-
uated. The validated mutations include F446I, N458Y, M476I, Y493H,
R539T, I543T, P553L, R561H, and C580Y, while the 11 associated/
candidates are P441L, G449A, C469F, A481V, P527H, N537I, G538V,
V568G, P574L, F673I, and A675V (WHO, 2018). Some of these muta-
tions have been identified in Africa countries, including, F446I, P574L,
M476I, and A675V (Ocan et al., 2019). In African countries the overall
prevalence of non-synonymous single nucleotide polymorphisms
(SNPs) was 7.6%, as reported in a systematic review of studies pub-
lished between 2014 and 2018 (Ocan et al., 2019). The most frequent
allele observed in African countries is A578S, although it has not been
associated with clinical or in vitro resistance to artemisinin or delayed
clearance (Ménard et al., 2016; WHO, 2017).
A drug e"cacy study conducted in Zambia in 2013 showed a few
late parasitological failure (7%) and late clinical failure (3.5%), with no
early clinical failures in younger patients treated with AL, suggesting
that AL remains safe and e"cacious for the treatment of uncomplicated
P. falciparum malaria (Hamainza et al., 2014). The e"cacy study
suggested the need for further sentinel and periodic monitoring of AL
e"cacy in di!erent areas of the country (Hamainza et al., 2014). Hence
this study examines the mutations in PfK13 associated with artemisinin
resistance.
P.falciparum multi drug resistance gene 1 (Pfmdr1) is one of the
markers associated with decreased sensitivity to lumefantrine, parti-
cularly Pfmdr1 N86 (Venkatesan et al., 2014). Parasites carrying
Pfmdr1 86 N gene are killed by treatment with AL but their increased
tolerance of residual drug levels allows them to re-infect a person more
rapidly after his treatment, compared to parasites carry 86Y form of the
gene. (Hastings and Ward, 2005). This points to Pfmdr1 86 N as a
Fig. 1. Map of Zambia showing the location of Southern and Western Provinces and the site where samples were collected.
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potential marker for lumefantrine resistance (Sisowath et al., 2005).
The P-glycoprotein-1 homologue transporter encoded by Pfmdr1 a!ects
the intra-parasitic concentration of some key antimalarials (Reed et al.,
2000). With multiple genetic loci associated with di!erential drug re-
sistance, this study sought to assess the presence of selected markers of
resistance to two antimalarials that are currently widely used in
Zambia, SP (markers Pfdhfr and Pfdhps) and AL (markers Pfk13 and
Pfmdr1), using data from a cross-sectional survey conducted in
Southern and Western provinces.
2. Materials and methods
2.1. Study area and participants
A cross-sectional, household survey to assess malaria elimination
e!orts was conducted in Zambia's Southern Province and Western
Province during peak malaria transmission from April to May 2017
(Fig. 1). At the time of the survey, Southern Province had the lowest
malaria prevalence in the country due to high coverage of various
control measures including vector control, case management at facility
and community levels, and targeted MDA with DHAP. In contrast,
Western Province had a moderate to high malaria prevalence, with
good vector control coverage and case management at the facility level
(MOH, 2018).
2.2. Sampling
2.2.1. Original survey sampling and sample collection
In Southern Province, a pre-existing sampling frame from another
study was used (the 2017 Southern Province survey) (Eisele et al.,
2015) whereby 52 households were randomly selected from each of the
60 health facility catchment areas. In Western Province, a de novo two-
stage, cluster-randomized design was used, with the probability of se-
lecting the primary sampling unity (standard enumeration area [SEA])
proportional to its relative size. The design was based on the 2010
census standard enumeration areas, with 25 households randomly se-
lected from each of the 24 SEAs after listing all households in each SEA
(Ministry of Health, 2015).
During the survey, three dried blood spots on filter paper were
obtained via finger prick from each participant, labelled with a parti-
cipant identification code, air dried, individually placed in tight closing
medicine pack with silica gel, and transported to the molecular lab
where they were stored at #20 °C. Malaria infection was diagnosed
using rapid diagnostic tests (SD Bioline Malaria Ag Pf, Standard
Diagnostics, Inc, Suwon city South Korea) on individuals of all ages in
the sampled households, yielding 6977 samples across the two pro-
vinces.
2.2.2. Study sampling
After excluding clusters with zero prevalence (by rapid diagnostic
test), 13 clusters were randomly selected from both provinces, yielding
1567 samples to be screened for Plasmodium species via photo-induced
electron transfer-polymerase chain reaction (PET-PCR). A subset of the
positives was later assayed for genetic markers of drug resistance using
high-resolution melt (HRM)-PCR. Only samples with P. falciparum in-
fections from the PET-PCR analysis were included.
2.3. Laboratory methods
Molecular analysis was conducted at the National Malaria
Elimination Centre Reference Laboratory in Lusaka, Zambia. Parasite
genomic DNA was extracted using a QIAamp DNA minikit (Qiagen,
Hilden, Germany) according to manufacturer instructions, with mod-
ifications. A 6 mm (approximately 13.8 µl of whole blood) punch was
extracted, either individually if the rapid diagnostic test result was
positive or in a pool of 10 if the rapid diagnostic test was negative.
Extracted DNA was eluted in 100 µl of elution bu!er before being tested
by PET-PCR as previously described (Lucchi et al., 2013). Positive pools
were de-convoluted as required. Samples were stored long-term at
#20 °C.
Extracted DNA was pre-amplified using diluted (0.2x) pooled for-
ward and reverse primers for Pfdhfr, Pfdhps, and Pfmdr1 using TaqMan
PreAmp Master Mix (Life Technologies, Foster City, CA, USA) as pre-
viously described by (Daniels et al., 2012). The total reaction volume
depended on the quantity of DNA. A 10 µl reaction volume was used for
samples with a PET-PCR cycle threshold (Ct) value > 35, whereas a
20 µl reaction volume was used for samples with a Ct < 35. The pre-
amplified DNA then was cleaned using a genomic DNA clean and
concentrator-10 kit (Zymo Research, Tustin, CA, USA), as per the
manufacturer's instructions.
The pre-amplified and cleaned samples were then amplified in a 5:1
asymmetric PCR, and HRM analysis performed on a LightScanner 380
system (Roche, Basel Switzerland) with 3$ mismatched probes specific
to mutations in Pfdhfr (N51I, C59R, I164L, and S108N), Pfdhps (S436F,
A437G, K540E/N, and A581G), and Pfmdr1 (N86Y, Y184F, and
D1246Y). 3D7, Dd2, HB3, and Tm90C6B were used as positive controls
for mutant and wild-type alleles; however, Pfdhps K540E/N only had a
control for the sensitive allele (K540). All PCR amplifications were
performed using 2.0 µL of LightScanner Master Mix (BioFireDefense
LLC, Salt Lake City, UT, USA), 2.5 µL of the pre-amplified template
(1:20 dilution), and 0.5 µL of primers and probes. The final primer
concentrations for a 5.0 µL total reaction volume were 0.5 µM of excess
primer, 0.1 µM of limiting primer, and 0.4 µM of the 3$ mismatched
probe. The following amplification conditions were used: 95 °C dena-
turation for 2 min, 45 cycles of 94 °C for 5 s and 66 °C (or 63 °C for
Pfdhfr S108N and Pfmdr1 D1246Y) for 30 s, and a pre-melt cycle of 5 s
each at 95 °C and 37 °C. Probe binding was measured as the change in
fluorescence against the sample temperature from 40 °C to 90 °C
(Daniels et al., 2012; Obaldia et al., 2015).
The PfK13 gene was amplified via nested PCR using the primary
PCR primers PfK13_PCR_F 5$-CGGAGTGACCAAATCTGGGA-3$ and
PfK13_PCR_R 5$-GGGAATCTGGTGGTAACAGC-3$ and nested PCR pri-
mers PfK13_N1_F 5$-GCCAAGCTGCCATTCATTTG-3$and PfK13_N1_R
5$-GCCTTGTTGAAAGAAGCAGA-3$. For both primary and nested reac-
tions, a 25 µL and 50 µL reaction volume was used, respectively, con-
taining a 1x final concentration bu!er of 2.5 mM of MgCl2, 20 nM of
deoxyribonucleotide triphosphates (dNTPs), 1.25 of UTaq® polymerase
(Solis BioDyne, Tartu, Estonia), and 250 nM of each primer, with 5 µL
of template (primary) and 1 µL of template (nested). Reactions were
undertaken on a MyCycler™ thermal cycler (Bio-Rad Laboratories,
Hercules, CA, USA) as follows: 15 min at 95 °C, 30 cycles of 30 s at
95 °C, 2 min at 58 °C, 2 min at 72 °C, and a final extension of 10 min at
72 °C, for the primary reaction. For the nested reaction, the conditions
were 15 min at 95 °C, then 40 cycles of 30 s at 95 °C, 1 min at 60 °C,
1 min at 72 °C, and a final extension of 10 min at 72 °C.
Inqaba Biotechnology Industries in South Africa cleaned up the
amplicons using the ZR-96 DNA Sequence Clean-up Kit Catalogue No.
D4053 (Zymo Research, Tustin, CA, USA) before injecting them onto an
ABI 3500XL Genetic Analyser (Applied Biosystems, Foster City, USA)
for sequencing. Due to the cost of sequencing, only 83 samples were
sent.
2.4. Data analysis
Allele prevalence was analysed using Stata version 13 (College
Station, TX, USA). Any sample that contained a mixed result (i.e. pre-
sence of both wild-type and mutant alleles) was scored as a mutant. Chi
square tests were used to compare di!erences between the two pro-
vinces. The confidence interval was set at 95%, and a P-value of % 0.05
was considered statistically significant.
Multiple nucleotide sequence alignments were analysed by
MacVector (Cambridge, UK) using the 3D7 PfK13 sequence (GenBank
L. Sitali, et al. $FWD7URSLFD

accession no. XM001350122) as a reference to detect point mutations
in the gene.
2.5. Ethical clearance
Ethical clearance was obtained from the regional committee for
medical and health research ethics Western Norway (Ref no. 2016/
1393/REK Vest), the University of Zambia biomedical research ethics
committee (Ref no. 010–05–16), as well as from the Tulane university
institutional review board (Ref no. 17–1,013,453). As this analysis was
part of a larger study, ethical clearance for the larger study also was
obtained from University of Zambia biomedical research ethics com-
mittee (Ref no. 010–12–17). Permission to use data was obtained from
the national health research authority and from the Ministry of Health.
All data were anonymized.
3. Results
3.1. Sample and isolate characteristics
A total 266 of 1567 isolates (17%) were positive for P. falciparum.
Of these, 181 (68%) were tested and >70% successfully characterised
for Pfdhfr, Pfdhps, and Pfmdr1 resistance markers (Table 1). For Kelch
13, 83 of the 266 samples (31%) were sent for analysis of which 70
returned high quality sequence data.
Of the 181 samples, 42 were from Southern Province and 139 were
from Western Province. Due to the small sample size for Southern
Province and the small non-significant di!erence in allele frequencies
between the two provinces (S1 table), data were analysed collectively.
3.2. Pfdhfr and Pfdhps mutations
Mutant alleles (Note-mixed samples were scored mutant) were ob-
served in PfdhpsA437G (93.2%) and Pfdhfr C59R (86.7%) N51I
(80.9%) and S108N (80.8%). Other mutations were rare (e.g.,
PfdhpsK540E/N [4.7%] and A581G [2.6%]) or not observed (e.g.,
Pfdhfrcodon164 [0%]) (Table 2). The mixed samples were observed in
the HRM PCR, where one sample had two di!erent peaks indicating
di!erent melting points.
Looking at Pfdhfr and Pfdhps separately, 11 haplotypes were ob-
served for each gene (Note-mixed sample were scored as mutant), from
wild-type to double (Pfdhps) or triple (Pfdhfr) mutants. For Pfdhfr, the
triple mutant N51I+C59R+S108N haplotype was the most prevalent
(75.2%), and the double haplotype C59R+S108N was least prevalent
(0.8%). For Pfdhps, the single haplotype A437G, also denoted as SGKA
was most prevalent (86.5%) (Table 2).
Amongst 87 isolates with complete results for Pfdhfr and Pfdhps
alleles tested, eight haplotypes of di!ering combinations of Pfdhfr and
Pfdhps mutant alleles were identified (triple, quadruple, and quin-
tuple), as shown in Table 3. The quadruple mutation N51I+C59R
+S108N+A437G (Pfdhfr + Pfdhps) was the most prevalent (82.4%).
From the haplotypes formed, no wild-type, single-mutant and double-
mutant haplotypes were observed, nor were the known high-grade re-
sistant septuple haplotypes.
3.3. Pfk13 mutations
Three isolates from Western Province had mutations in the Pfk13
gene, of which two were synonymous and one was non-synonymous
(Table 4).
3.4. PfMDR1 mutations
Of the approximately 150 samples that were typed at the Pfmdr1
locus, there was no evidence of the Pfmdr1 N86Y mutation, and Pfmdr1
D1246Y was observed in only three samples. In contrast, Pfmdr1 Y184F
was identified in 43.2% of isolates (Table1). In terms of haplotypes,
97% of all samples were either wild-type NYD (55.3%) or single mutant
NFD (42.0%) (Fig. 2).
4. Discussion
Drug-resistant malaria parasites pose a serious public health chal-
lenge for control and elimination of malaria. This study reports the
prevalence of Pfdhfr, Pfdhps, Pfmdr1, and PfK13 gene mutations as-
sociated with drug resistance from field isolates collected in Western
Province and Southern Province in Zambia in 2017 from cross-sectional
household surveys. Surveillance of drug resistance markers allows for
early detection of drug resistance and is vital for providing evidence for
policy change.
Consistent with previous findings from Zambia (Siame et al., 2015)
and the Democratic Republic of the Congo (Nkoli Mandoko et al., 2018;
Ruh et al., 2018), in this study, Pfdhfr mutations had a high prevalence
(~80%), whereas, except for A437G, Pfdhps mutants were relatively
rare (<5%). The prevalence of the three Pfdhfr mutations (N51I, C59R,
and S108N) increased from under 20% to approximately 80% between
1988 and 2005, after which prevalence remained high but did not reach
100% (Fig. 2). With the exception of a single survey in 2006, Pfdhps
A437G prevalence also increased dramatically. These trends correlate
well with a strong selection pressure until 2003 when SP was replaced
by AL.
Mutations associated with SP resistance are evolutionarily acquired
in a stepwise fashion. For Pfdhfr, selection occurs first at codon 108,
then codon 51 or 59, and then others; while for Pfdhps, mutations occur
first at codon 437 (Sirawaraporn et al., 1997). Looking at both genes,
the quadruple mutant haplotype [Pfdhfr + Pfdhps (N51I+C59R
+S108N+ A437G)] dominated the isolates, with few quintuple mu-
tants and no sextuple or septuple mutants. This quintuple haplotype has
Table 1
Overall frequency of individual Pfdhfr, Pfdhps, and Pfmdr1 mutations in iso-
lates.
Gene Loci Successfully assayed (N) Mutant n (%) 95% CI
Pfdhfr N51I 136 110 (80.9) 73.3 – 87.1
C59R 128 111 (86.7) 79.6 – 92.0
S108N 172 139 (80.8) 74.1 – 86.4
I164L 129 0 (0) 0- 2.8
Pfdhps S436F 146 2 (1.4) 0.17 #4.9
A437G 146 136 (93.2) 87.8 – 96.7
K540E/N 171 8 (4.7) 2.0 #9.0
A581G 154 4 (2.6) 0.7 – 6.5
Pfmdr1 N86Y 140 0 (0) 0–2.6
Y184F 132 57 (43.2) 34.6–52.1
D1246Y 150 3 (2.0) 0.4–5.7
Table 2





n (%) 95% CI
Pfdhfr n = 124 Wild type 3 (2.4) 0.5–6.9
C59R Single 2 (1.6) 0.2–5.7
S108N Single 13 (10.5) 5.7–17.3
C59R+S108N Double 1 (0.8) 0.02–4.4
N51I+C59R Double 11 (8.9) 4.5–15.3
N51I+C59R+S108N Triple 94 (75.2) 67.3–83.0
Pfdhps n = 133 Wild type 6 (4.5) 1.7–9.5
A437G Single 115 (86.5) 79.5–91.8
S436F+A437G Double 2 (1.5) 0.2–5.3
A437G+A581G Double 3 (2.3) 0.5–6.5
A437G+K540E/N Double 7 (5.3) 2.1- 10.5
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been strongly linked to SP treatment failure (Wang et al., 1997). There
was no evidence for Pfdhfr I164L, a rare mutation in Africa, that is also
highly correlated with phenotypic resistance (Hyde, 1990).
These findings suggest past or current pressure to select for SP-re-
sistant mutants, consistent with results from previous studies
(Depoortere et al., 2004; Mkulama et al., 2008; Siame et al., 2015)
(Figs. 2 and 3). As SP is available without a prescription and is widely
used to self-medicate, despite its o"cial exclusive use in IPTp
(Alifrangis et al., 2014), while antifolate drugs like co-trimoxazole are
commonly used to manage bacterial infections and prevent opportu-
nistic infections amongst HIV patients in Zambia (Khalil et al., 2003),
the opportunity for selection pressure exists. However, selection is not
absolute, as not all mutations are fixed in the population and higher-
order mutants appear to be absent. Taken together, the results suggest
that SP could still provide a benefit (e.g., in IPTp (Mace et al., 2015;
Siame et al., 2015; Tan et al., 2014). It is likely still e"cacious
(Tan et al., 2014) and any additional mutations would threaten its
utility. In addition, the major predictors for IPTp failure (Pfdhps E540
and A581 or the quintuple haplotype) were rare (<4%). WHO re-
commends stopping IPTp with SP if Pfdhps K540E is over 95% and
Pfdhps A581G is over 10% (WHO, 2013) and introduction of IPTi-SP in
areas where mutations at codon 540 in the Pfdhps gene are 50% or less
(WHO, 2011).
Three mutations not linked to late parasite clearance were detected
in PfK13; non-synonymous A578S and synonymous T478 and V666.
A578S has been observed at low frequencies in Africa (WHO, 2018), for
instance in Gabon (Voumbo-Matoumona et al., 2018), Kenya
(Muwanguzi et al., 2016), Mali (Ouattara et al., 2015), and Uganda
(Conrad et al., 2014) and was also previously identified in Zambia in
2016 (Hawela et al., unpublished data). A578 has not been associated
with clinical or in vitro resistance to artemisinin (Ménard et al., 2016).
The synonymous mutation V666 has been identified in Nigeria
(Oboh et al., 2018) and Mozambique (Gupta et al., 2018), and T478 has
been reported in Kenya and Cote d'lvoire (Kamau et al., 2015). Criti-
cally, none of these mutations alter protein function, suggesting that
artemisinin remains highly unlikely. In addition, from a genetic per-
spective, the observed low frequency of the mutations could be attrib-
uted to negative selection and since P. falciparum is not a single po-
pulation, there is evidence of local population expansions could lead to
genes that show di!erent mutations at low frequencies (Pacheco et al.,
2019).
Pfmdr1 haplotype NFD associated with reduced susceptibility to
Lumefantrine was found as 42.0%, consistent with finding from Ghana
(Osarfo et al., 2018) and Mainland Tanzania (Ishengoma et al., 2019).
This result is also consistent with reports from Ghana (Osarfo et al.,
2018) and Rwanda (Zeile et al., 2012). While, to the best of our
knowledge, AL remains e"cacious in Zambia (Banda et al., 2019), the
presence of these mutations associated with lumefantrine resistance
calls for close monitoring of AL.
4.1. Study limitations
All samples were PCR pre-amplified, which could have introduced
an amplification bias for certain alleles. Pfdhfr 540 only had a single
control (wild type) and with results showing additional peaks, it was
di"cult to discriminate between K540E and K540N, hence the assign-
ment of K50E/N. The study did not assess piperaquine resistance de-
spite the use of DHAP for the MDA study, however at the time of field
work for the surveys, it had only been used for three years and only in a
few areas in Southern Province.
5. Conclusions
A high proportion of samples in our study contained multiple an-
tifolate-resistant markers, although higher-order combinations most
Table 3
Pfdhfr and Pfdhps genotypes from 87 isolates with complete genotypes from Southern Province and Western Province, Zambia.
Pfdhfr mutations Pfdhps mutations
N 51 59 108 164 436 437 540 581 % (95% CI)
Triple 1 – – + – + + – - S108N+S436F+A437G 1.2 (0.03 – 6.4)
1 – + + – – + – – C59R+S108N+A437G 1.2 (0.03 – 6.4)
1 + – – – – – + + N51I+K540E/N + A581G 1.2 (0.03 – 6.4)
1 – + – – – + + – C59R+A437G+K540E/N 1.2 (0.03 – 6.4)
2 – – + – – + + – S108N+A437G+K540E/N 2.3 (0.3 - 0.8.2)
6 + + – – – + – – N51I+C59R+A437G 7.1 (2.6 #14.7)
Quadruple 70 + + + – – + – – N51I+C59R+S108N+A437G 82.4 (76 - 91)
Quintuple 1 + + + – + + – – N51I+C59R+S108N+S436F+A437G 1.2 (0.03 – 6.4)
1 + + + – – + – + N51I+C59R+S108N+A437G+A581G 1.2 (0.03 – 6.4)
3 + + + – – + + – N51I+C59R+S108N+A437G+K540E/N 3.5 (0.7 – 10.0)
Table 4
Proportion of polymorphisms observed in the kelch 13 gene in isolates from Southern Province and Western Province, Zambia.
Target gene Pfk13 Pfk13 Codon Locus Nucleotide n (%) Reference sequence Mutant sequence Reference amino acid Mutant amino acid
478 1434 1 (1.4) ACC ACG Threonine Threonine
578 1732 1 (1.4) GCT TCT Alanine Serine
666 1998 1 (1.4) GTA GTC Valine Valine
Fig. 2. P. falciparumPfmdr1 haplotypes in Southern and Western Provinces of
Zambia.
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clearly associated with treatment failure were missing. This suggests
that while SP is likely still e"cacious, any additional mutations would
threaten its utility due to increased parasite resistance. While no mar-
kers for artemisinin resistance were identified, a significant proportion
of the study population contained a mutation associated with reduced
sensitivity to lumefantrine, which calls for close monitoring of AL.
Monitoring genotypic markers of resistance during the routine
therapeutic e"cacy studies recommended by WHO will be critical in
ensuring malaria infections continue to be treated with an e"cacious
drug.
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The findings in this manuscript add to the body of knowledge in the
sense that they give an update on the resistance markers in Zambia. The
findings show that there moderate Sulfadoxine-Pyrimethamine re-
sistance and absence of Artemisinin resistance markers. This informa-
tion is likely to be of great interest to the health systems in Zambia and
to the international scientific community.
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